Carbimazole is an anti-thyroid agent. It is indicated in all conditions where reduction of thyroid function is required.
Such conditions are:
For this indication, competent medicine agencies globally authorize below treatments:
For: Adults (18-64) Elders (65+)
20 - 60 mg
From 6.667 To 20 mg 3 time(s) per day every day for 180 day(s)
The initial dose is in the range 20 mg to 60 mg, taken as two to three divided doses. The dose should be titrated against thyroid function until the patient is euthyroid in order to reduce the risk of over-treatment and resultant hypothyroidism.
Subsequent therapy may then be administered in one of two ways.
Final dosage is usually in the range 5 mg to 15 mg per day, which may be taken as a single daily dose. Therapy should be continued for at least six months and up to 18 months. Serial thyroid function monitoring is recommended, together with appropriate dosage modification in order to maintain a euthyroid state.
Dosage is maintained at the initial level, i.e. 20 mg to 60 mg per day, and supplemental L-thyroxine, 50 mcg to 150 mcg per day, is administered concomitantly, in order to prevent hypothyroidism. Therapy should be continued for at least six months and up to 18 months. Where a single dosage of less than 20 mg is recommended, it is intended that carbimazole 5 mg should be taken.
For: Children Adolescents
15 - 15 mg
From 15 To 15 mg once every day
The usual initial daily dose is 15 mg per day adjusted according to response.
Safety and efficacy of carbimazole in children below 2 years of age have not been evaluated systematically. Use of carbimazole in children below 2 years of age is therefore not recommended.